Neuroprotective Agents Market
Number of pages: 100 | Report Format: PDF | Published date: 14 March, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 81.57 billion |
|
Revenue forecast in 2031 |
US$ 143.78 billion |
|
Growth Rate |
CAGR of 6.5% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Drug Class, Application, Route of Administration, Distribution Channel, and Region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global neuroprotective agents market was valued at US$ 81.57 billion in 2022 and is expected to register a revenue CAGR of 6.5% to reach US$ 143.78 billion by 2031.
Market Fundamentals
Neuroprotective agents are medications that can modify the course of metabolic events following the beginning of ischemia, potentially reducing stroke damage. Calcium channel blockers, naloxone, gangliosides, glutamate antagonists, and free radical scavengers are examples of these agents. Each of these agents has shown promise in the laboratory, but none has proven therapeutically effective. Several treatments are beneficial in preventing neuronal cell death in animal models, but supporting data from clinical studies is still lacking. Over the previous decade, new medications have been launched, resulting in better patient outcomes.
Glutamate blockers such as polyarginine R18 and NA-1 (TAT-NR2B9c) have been utilized in stroke models in rats, nonhuman primates, and humans. Milani and colleagues identified R18 as a possible neuroprotective drug. Both investigations on rats found that administering R18 60 minutes after a stroke reduced infarct volume and cerebral edema, improved functional outcomes, and was more effective than NA-1. These drugs exhibit anti-excitotoxicity by inhibiting the postsynaptic density-95 protein/nNOS complex. This class of neuroprotective medicines works by reducing oxidative stress in mitochondria, reducing calcium influx owing to glutamate excitotoxicity, and inhibiting proprotein convertases through proteolytic activity.
Immunosuppressive medications such as cyclosporine A (CsA) and, particularly, tacrolimus (FK506) have been widely employed in animal models as neuroprotective treatments in ischemic brain lesions. Tacrolimus and cyclosporine are both calcineurin inhibitors. These drugs bind to immunophilins and inhibit calcineurin, decreasing interleukin 2 production and T cells. Tacrolimus is a macrolide antibiotic with more potency than cyclosporin and a different method of immunophilin receptor blockage than cyclosporin. Both medicines are cytochrome P450 3A4 substrates with potential renal and hepatic adverse effects. On the contrary, free radical scavengers such as polyethylene glycol (PEG)-conjugated SOD (PEG-SOD), 4-hydroxy- 2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol), trans-2,3′,4, 5′-tetrahydroxystilbene (hydroxystilbene oxyresveratrol), and NXY-059 have been employed as neuroprotectants in animal research. PEG-SOD, tempol, and hydroxystilbene oxyresveratrol had no effect on neuropathology.
[67856]
Market Dynamics
The increasing prevalence of neurological illnesses is projected to boost market expansion. Neurological disorders are a primary cause of disability and death worldwide. Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis are the "big three" neurodegenerative disorders that cause major morbidity and mortality in the elderly population worldwide. Neuroprotective medications are those that aid in the preservation of the structure and function of neurons. Neuroprotective drugs can potentially prevent the 6 million stroke deaths each year. Every year, around 50 million people worldwide suffer from epilepsy, according to World Health Organization figures released in February 2022.
Additionally, because of the increasing prevalence of neurological illnesses, various academics, and manufacturers have increased their research and development efforts to develop neurological problem drugs for therapy. Many businesses worldwide have submitted applications for the most promising neurological disorder treatments, which are now undergoing regulatory approval at various levels. Nonetheless, some manufacturers have previously released drugs for neurological illnesses. Improved neurological disorder medication research and development efforts are projected to address the demand for neurological disorder pharmaceuticals while also boosting supply at the most competitive pricing. As a result, increased research and development for neurological disorder drugs drive the market.
Furthermore, according to NHS England estimates from April 2022, around 1 in 12,500 individuals in England will experience a ruptured brain aneurysm each year. In addition, approximately 3.0% of adults in the United Kingdom have a brain aneurysm. Furthermore, an estimated 6 million Americans are impacted by brain aneurysms each year, according to Brain Aneurysm Foundation figures revised in May 2020. Furthermore, according to the Parkinson's Foundation Statistics updated in April 2020, more than one million people in the United States will be living with Parkinson's disease by 2020, and nearly 60,000 Americans will be diagnosed with Parkinson's disease each year.
Market Ecosystem
The global neuroprotective agents market has been analyzed from five perspectives: Drug Class, Application, Route of Administration, Distribution Channel, and Region.
Neuroprotective Agents Market by Drug Class
[86755]
The global neuroprotective agents market has been segmented based on drug class into anesthetics, antidepressants, cytokines, cholinesterase inhibitors, NMDA receptors antagonists, anti-inflammatory and anti-apoptotic agents, and others.
The cholinesterase inhibitors are likely to dominate the market during the forecast period. Cholinesterase inhibitors are taken by those suffering from Alzheimer's disease. Some acetylcholine-using nerve cells are lost in Alzheimer's disease. Alzheimer's disease symptoms worsen over time due to these alterations in the brain. Donepezil, rivastigmine, and galantamine all inhibit the breakdown of acetylcholine by an enzyme called acetylcholinesterase. This means that the brain has a larger acetylcholine concentration, leading to improved communication between nerve cells. This may temporarily alleviate some symptoms of Alzheimer's disease. The three cholinesterase inhibitors all function in the same way.
Additionally, NMDA receptors are predicted to have the greatest market share during the projection period. The first class of therapeutic medicines for acute stroke is NMDA receptor antagonists. They applied modern clinical trial design techniques, progressed from laboratory to human testing, and provided early treatment.
Neuroprotective Agents Market by Application
The global neuroprotective agents market has been segmented based on application into Alzheimer’s disease, epilepsy, multiple sclerosis, brain injury, stroke, and others.
The Alzheimer’s disease segment will likely dominate the market during the forecast period. Alzheimer's disease is becoming more common and is predicted to continue in the future. According to the World Health Organization, approximately 50 million people worldwide will live with Alzheimer's disease and other dementias in 2020, which is anticipated to rise to more than 152 million by 2050. Furthermore, according to a study published in Ageing Research Reviews, 2020, Alzheimer's disease progresses with age and is the fifth-largest contributor to the worldwide illness burden.
Neuroprotective Agents Market by Route of Administration
Based on the route of administration, the global neuroprotective agents market has been segmented into oral, topical, epidural, and intravenous.
The oral segment is expected to dominate the market during the forecast period. Oral medication is the most prevalent way of drug administration. The segment’s growth can be attributed to its advantages such as the convenience of drug administration via the oral route, patient preference, cost-effectiveness, and ease of large-scale manufacture of oral dosage forms.
Neuroprotective Agents Market by Distribution Channel
Based on distribution channel, the global neuroprotective agents market has into hospital pharmacies, retail pharmacies, and online pharmacies.
The retail pharmacies segment dominates the market during the forecast period due to the rising population and patient pool and the affordability of medicines. Because of the developing medical infrastructure and the introduction of patented drugs, consumers now have better access to medicines. The hospital pharmacies segment showed lucrative growth during the forecast period. The segment’s growth can be attributed to the availability of more operating capital to invest in cutting-edge medical technologies. Hospitals hold essential medical equipment to offer patients complete care because they are frequently multi-specialty centers.
Neuroprotective Agents Market by Region
The global neuroprotective agents market has been segmented based on region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is estimated to account for a sizable portion of the global neuroprotective agents market. According to the Parkinson's Foundation, almost one million people in the United States will have Parkinson's disease by 2020, which is higher than the combined number of people with multiple sclerosis, muscular dystrophy, and Lou Gehrig's disease. By 2030, the figure is predicted to climb to 1.2 million. Each year, approximately 60,000 people are diagnosed with Parkinson's disease, with the total direct and indirect cost of Parkinson's disease, including treatment, social security payments, and lost income, estimated to be nearly USD 52 billion in the United States alone. More than 10 million people worldwide suffer from Parkinson's disease.
According to a World Health Organization (WHO) and Pan American Health Organization (PAHO) survey conducted in May 2020, psychotherapy and counseling services have been partially or completely disrupted in more than half of North American countries (60.7%), while diagnostic and laboratory services at mental health facilities have been disrupted in 11 of 28 countries (39.3%).
Moreover, the government's funding and support for research initiatives are expanding because of the disease's growing burden. The United States controls the majority of the worldwide neuroprotective agents market. According to the July 2020 report of the United States National Institute of Mental Health (NIMH), one in every four Americans has a diagnosable mental disease in any given year, and approximately 6% have a severe disability. According to the same estimate, the annual cost of severe mental illness in the United States surpasses USD 317 billion. According to the World Health Organization (WHO) and Pan American Health Organization (PAHO) May 2020 survey, psychotherapy, and counseling services have been partially or completely disrupted in more than half of North American countries (60.7%), while diagnostic and laboratory services at mental health facilities have been disrupted in 11 of 28 countries (39.3%).
The Asia Pacific neuroprotective agents market is expected to rise rapidly throughout the projected period. The presence of a well-established pharmaceutical and biotechnology industry, increased research activity, increased prevalence of neurological disorders, and a growing demand for highly efficient drugs for the target-specific treatment of disorders are all expected to boost demand for neuroprotection drugs in the region.
Competitive Landscape
The neuroprotective agents market is fragmented with a few prominent participants. In terms of market share, the market is currently dominated by a few significant competitors. As large pharmaceutical companies expand their product portfolios through increased product development in developed markets such as North America and Europe, as well as an increased strategic partnership with regional competitors in developing nations. North America, Europe, and Asia Pacific are expected to account for most of the global neuroprotective agents market. Increased pharmacological trials, increased awareness of neurological illnesses, and improved healthcare infrastructure in emerging nations such as India are expected to fuel the growth Some of the prominent market players in the globalneuroprotective agents market include
Strategic Development
Neuroprotective agents are medications that can modify the course of metabolic events following the beginning of ischemia, potentially reducing stroke damage.
The Alzheimer’s disease application led the global neuroprotective agents market.
The CAGR of the neuroprotective agents market during the forecast period will be 6.5%.
Some prominent market players in the global neuroprotective agents market include Merck KGaA, Novartis Pharmaceuticals Corporation, Eisai Inc., and others.
The Asia Pacific is the key global neuroprotective agents market growth region.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst